May 1, 2018 / 12:25 PM / a month ago

BRIEF-Biogen And Neurimmune Announce Option Exercise For Alzheimer's Disease Investigational Treatment Aducanumab

May 1 (Reuters) - Biogen Inc:

* BIOGEN AND NEURIMMUNE ANNOUNCE OPTION EXERCISE FOR ALZHEIMER’S DISEASE INVESTIGATIONAL TREATMENT ADUCANUMAB

* BIOGEN - WILL MAKE A ONE-TIME $50 MILLION PAYMENT TO NEURIMMUNE FOR 5% REDUCTION IN ORIGINAL ROYALTY RATES ON POTENTIAL COMMERCIAL SALES OF ADUCANUMAB

* BIOGEN INC - HAS EXERCISED ITS OPTION TO FURTHER REDUCE PREVIOUSLY NEGOTIATED ROYALTY RATES PAYABLE ON POTENTIAL FUTURE SALES OF ADUCANUMAB Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below